Assay enables researchers to study all kinases and ATPases, providing new approach to analyzing oncology targets
Bagnols-sur-Cèze, France – January 16, 2008 – Cisbio, a global developer of HTRF® (Homogeneous Time-Resolved Fluorescence) technology and services used in assay development and drug screening, announced the launch of the HTRF® Transcreener™ ADP assay, a universal and flexible assay for the high-throughput screening and profiling of kinases. This assay solution enables pharmaceutical and biotechnology researchers to study all kinases, a key area of interest in oncology research.
HTRF® Transcreener™ ADP is a homogeneous, non-radioactive solution for kinases and ATPases. The assay measures the generation of ADP (Adenosine 5’-diphosphate), which is directly detected by a specific antibody labelled with Eu3+ cryptate and correlates tightly with the amount of phosphorylated substrate. By measuring ADP and not the substrate itself, the assay is compatible with any substrate. The enzyme-free detection mode also provides an alternative with less interference and a lower false positive rate than assays which measure ATP depletion. This is particularly suitable when measuring difficult kinases, such as ones where no specific antibody is available.
HTRF® Transcreener™ ADP combines two technologies: HTRF®, Cisbio’s proprietary, highly sensitive, robust technology for the detection of molecular interactions in vitro which is widely used for primary and secondary screening phases of drug development; and Transcreener™, a proprietary ADP immunodetection technology platform for kinases and other ATP-utilizing enzymes developed and patented by BellBrook Labs, a leading provider of HTS tools for the drug discovery industry.
“Transcreener™, like HTRF®, is a reliable and robust technology, which is why our partnership with BellBrook makes sense,” said François Degorce, head of HTRF® marketing and business development at Cisbio. “We are always looking to complement our kinase offering and reinforce our expertise in this field, and the combination of two such powerful technologies means that HTRF® Transcreener™ ADP will do just that, all while providing the research community with an equally powerful tool.”
Cisbio has developed an extensive range of HTRF®-based products addressing kinase needs since its technology was first proven in kinase screening in the mid-1990s. These HTS tools have enabled researchers to address over 160 different Tyrosine (Tyr) and Serine/Threonine (Ser/Thr) kinases. As it is based on the same technology platform, HTRF® Transcreener™ ADP does not require additional training or technology for existing HTRF® customers to use it. This means that adoption of the assay is straightforward, and researchers can now use a single technology for all kinase assays, and save valuable development time and costs.
The HTRF® Transcreener™ ADP assay is sold through Cisbio’s own sales networks in the United States and Europe, and through its exclusive distributors in India and Japan.
Cisbio is a global developer of products and technologies used in nuclear medicine, in vitro diagnostics and assay development for drug screening procedures. The company pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF®, a highly sensitive, robust technology for the detection of molecular interactions and widely used by the pharmaceutical industry for the high throughput screening stage of drug development. In addition, Cisbio produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs). For more information about Cisbio and HTRF®, log onto www.cisbio.com and www.htrf.com.
HTRF® is a registered trademark of Cisbio.
Transcreener™ is a trademark of BellBrook Labs, Inc.